ImmunityBio Launches $100 Million Public Offering with Goodwin
Deal News | Dec 12, 2024 | Goodwin
Goodwin's Capital Markets team successfully advised the underwriters on ImmunityBio's underwritten public offering, which involved the sale of 33,333,334 shares of common stock at $3.00 per share. The offering generated gross proceeds of $100 million. ImmunityBio, a biotechnology company focused on harnessing the immune system to treat cancer and infectious diseases, sought to fortify its capital base through this offering. The deal saw the participation of a syndicate of underwriters under the leadership of Bryan Quinn from Goodwin, with key team members including Justin Anslow, Harper Vincent, Daniel Karelitz, and Maggie Wong.
Sectors
- Biotechnology
- Legal Advisory
- Financial Services
Geography
- United States – ImmunityBio is listed on Nasdaq, a major U.S. stock exchange, and Goodwin is a U.S.-based law firm, indicating the geographic focus of the public offering.
Industry
- Biotechnology – The article discusses ImmunityBio, a biotechnology company focused on developing therapies that enhance the immune system to combat cancers and infectious diseases.
- Legal Advisory – Goodwin is a law firm providing legal advisory services, specifically in capital markets, as evidenced by their role in the public offering of ImmunityBio.
- Financial Services – The involvement of joint lead book-running managers and an underwriting syndicate points to the financial services industry, which is integral to managing public offerings.
Financials
- $100.0 Million – Gross proceeds from ImmunityBio's public offering.
- $3.00 – Price per share during the public offering.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ImmunityBio | Target Company | Company | A biotechnology company engaging in next-generation therapies targeting the immune system. |
| Goodwin | Legal Advisor | Company | A law firm that advised the underwriters in ImmunityBio's public offering. |
| Bryan Quinn | Lead Advisor | Person | Led the Capital Markets team at Goodwin during the ImmunityBio public offering. |
| Justin Anslow | Team Member | Person | Part of the Goodwin team advising on the public offering. |
| Harper Vincent | Team Member | Person | Part of the Goodwin team advising on the public offering. |
| Daniel Karelitz | Team Member | Person | Part of the Goodwin team advising on the public offering. |
| Maggie Wong | Team Member | Person | Part of the Goodwin team advising on the public offering. |